SI1776383T1 - Vezavne molekule - Google Patents
Vezavne molekuleInfo
- Publication number
- SI1776383T1 SI1776383T1 SI200531906T SI200531906T SI1776383T1 SI 1776383 T1 SI1776383 T1 SI 1776383T1 SI 200531906 T SI200531906 T SI 200531906T SI 200531906 T SI200531906 T SI 200531906T SI 1776383 T1 SI1776383 T1 SI 1776383T1
- Authority
- SI
- Slovenia
- Prior art keywords
- binding molecules
- molecules
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0416392A GB2416768A (en) | 2004-07-22 | 2004-07-22 | Heavy chain immunoglobulin complexes |
GB0511881A GB0511881D0 (en) | 2005-06-10 | 2005-06-10 | Binding molecules |
EP05766644.8A EP1776383B1 (en) | 2004-07-22 | 2005-07-22 | Binding molecules |
PCT/GB2005/002892 WO2006008548A2 (en) | 2004-07-22 | 2005-07-22 | Binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1776383T1 true SI1776383T1 (sl) | 2014-12-31 |
Family
ID=35431831
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200532162T SI2311874T1 (sl) | 2004-07-22 | 2005-07-22 | Vezavne molekule |
SI200531906T SI1776383T1 (sl) | 2004-07-22 | 2005-07-22 | Vezavne molekule |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200532162T SI2311874T1 (sl) | 2004-07-22 | 2005-07-22 | Vezavne molekule |
Country Status (21)
Country | Link |
---|---|
US (7) | US20090285805A1 (sl) |
EP (6) | EP2311874B1 (sl) |
JP (3) | JP2008512987A (sl) |
KR (4) | KR101457753B1 (sl) |
CN (2) | CN102659941B (sl) |
AU (2) | AU2005263994B2 (sl) |
BR (1) | BRPI0513577A (sl) |
CA (1) | CA2580336C (sl) |
CY (2) | CY1115762T1 (sl) |
DK (3) | DK1776383T3 (sl) |
ES (3) | ES2635497T3 (sl) |
HU (1) | HUE034335T2 (sl) |
LT (1) | LT2311874T (sl) |
MX (2) | MX2007000921A (sl) |
PL (2) | PL1776383T3 (sl) |
PT (2) | PT1776383E (sl) |
RU (1) | RU2398882C2 (sl) |
SG (1) | SG188080A1 (sl) |
SI (2) | SI2311874T1 (sl) |
WO (1) | WO2006008548A2 (sl) |
ZA (3) | ZA200701186B (sl) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
KR101457753B1 (ko) * | 2004-07-22 | 2014-11-03 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 결합 분자 |
ES2539250T3 (es) | 2005-07-25 | 2015-06-29 | Emergent Product Development Seattle, Llc | Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20 |
GB0601513D0 (en) * | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
BRPI0706750A2 (pt) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
GB0618345D0 (en) * | 2006-09-18 | 2006-10-25 | Univ Erasmus | Binding molecules |
CA2654317A1 (en) * | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
WO2009138519A1 (en) | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
WO2008074839A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
US9156914B2 (en) | 2006-12-19 | 2015-10-13 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
GB0706628D0 (en) * | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
PT2152880E (pt) | 2007-06-01 | 2011-12-15 | Omt Inc | Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos |
WO2009013620A2 (en) * | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
AU2008270274B2 (en) | 2007-07-03 | 2012-06-28 | Ablynx N.V. | Providing improved immunoglobulin sequences by mutating CDR and/or FR positions |
AU2008328781A1 (en) * | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
WO2009080832A1 (en) | 2007-12-26 | 2009-07-02 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells |
KR20100097753A (ko) | 2007-12-26 | 2010-09-03 | 바이오테스트 아게 | Cd138 표적성 면역접합체 및 이의 용도 |
ES2475201T3 (es) | 2007-12-26 | 2014-07-10 | Biotest Ag | Agentes dirigidos contra CD138 y usos de los mismos |
EP2947097A1 (en) | 2008-04-07 | 2015-11-25 | Ablynx N.V. | Amino acid sequences directed against the Notch pathways and uses thereof |
CN105198997B (zh) | 2008-04-11 | 2018-08-31 | 阿普拜佛研发有限责任公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
AU2009248834B2 (en) | 2008-05-23 | 2014-10-30 | Ablexis Llc | Method of generating single VL domain antibodies in transgenic animals |
AU2009254501B2 (en) | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
RU2011129459A (ru) | 2008-12-18 | 2013-01-27 | Эрасмус Юниверсити Медикал Сентр Роттердам | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение |
CN102257003B (zh) | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
WO2010079149A1 (de) | 2009-01-09 | 2010-07-15 | Ipk Gatersleben | Fusionsantikörper |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
SG181477A1 (en) * | 2009-12-10 | 2012-07-30 | Regeneron Pharma | Mice that make heavy chain antibodies |
EP2513145B1 (en) | 2009-12-14 | 2018-01-24 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
CN105001330B (zh) * | 2010-04-23 | 2020-05-01 | 弗·哈夫曼-拉罗切有限公司 | 生产异源多聚体蛋白质 |
EP2601298B1 (en) | 2010-08-02 | 2016-11-30 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
PE20140772A1 (es) | 2010-11-08 | 2014-07-03 | Novartis Ag | Polipeptidos que se enlazan a cxcr2 |
WO2012122512A1 (en) * | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
WO2012156981A1 (en) | 2011-05-13 | 2012-11-22 | Cadila Healthcare Limited | Pharmaceutical compositions of lurasidone |
CA2846319A1 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2013121440A1 (en) | 2012-02-13 | 2013-08-22 | Cadila Healthcare Limited | Process for preparing benzisothiazol-3-yl-peperazin-l-yl-methyl-cyclo hexyl-methanisoindol-1,3-dione and its intermediates |
PT2825559T (pt) * | 2012-03-13 | 2019-06-07 | Novimmune Sa | Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
EA201990959A1 (ru) | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
PT3653049T (pt) | 2012-12-14 | 2023-11-14 | Omniab Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
EP2967012B1 (en) | 2013-03-14 | 2020-09-16 | Erasmus University Medical Center Rotterdam | Transgenic non-human mammal for antibody production |
US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
AU2014332458B2 (en) * | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
US10822399B2 (en) | 2014-02-10 | 2020-11-03 | Igm Biosciences, Inc. | IgA multi-specific binding molecules |
KR102601491B1 (ko) | 2014-03-21 | 2023-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
JP6640181B2 (ja) * | 2014-03-21 | 2020-02-05 | エックス−ボディ インコーポレイテッド | 二重特異性抗原結合ポリペプチド |
JP2017510273A (ja) | 2014-03-21 | 2017-04-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 異なる結合特性を示すvl抗原結合タンパク質 |
WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
IL251010B2 (en) | 2014-10-22 | 2024-01-01 | Crescendo Biologics Ltd | transgenic mice |
CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
WO2017020001A2 (en) | 2015-07-29 | 2017-02-02 | Allergan, Inc. | Heavy chain only antibodies to ang-2 |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
AU2016307943A1 (en) | 2015-08-14 | 2018-02-15 | Allergan, Inc. | Heavy chain only antibodies to PDGF |
BR112018005573A2 (pt) | 2015-09-21 | 2019-01-22 | Aptevo Research And Development Llc | ?polipeptídeos de ligação a cd3? |
CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
MX2019002256A (es) * | 2016-08-24 | 2019-10-09 | Teneobio Inc | Animales transgenicos no humanos que producen anticuerpos modificados solo de cadena pesada. |
CN114395048A (zh) | 2016-09-14 | 2022-04-26 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
EP3332637A1 (en) * | 2016-12-09 | 2018-06-13 | Universitätsklinikum Hamburg-Eppendorf | Vhh-containing heavy chain antibody and production thereof |
KR102633423B1 (ko) | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
EP3570668A1 (en) | 2017-01-19 | 2019-11-27 | Open Monoclonal Technology, Inc. | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
JP2020516654A (ja) | 2017-04-13 | 2020-06-11 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
EP3642237A2 (en) | 2017-06-20 | 2020-04-29 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
CA3075399A1 (en) | 2017-09-13 | 2019-03-21 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
RU2756100C1 (ru) | 2017-12-20 | 2021-09-28 | Харбор Байомед (Шанхай) Ко., Лтд | Антитела, связывающие ctla-4, и их применение |
US11873336B2 (en) | 2017-12-22 | 2024-01-16 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
TW201930358A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對tigit之單域抗體及其變異體 |
KR20200120641A (ko) | 2018-01-15 | 2020-10-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
KR102115300B1 (ko) * | 2018-06-01 | 2020-05-26 | 재단법인 목암생명과학연구소 | 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법 |
CA3101859A1 (en) * | 2018-06-13 | 2019-12-19 | Crystal Bioscience Inc. | Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion |
EP3823990A1 (en) | 2018-07-20 | 2021-05-26 | TeneoBio, Inc. | Heavy chain antibodies binding to cd19 |
GB2576914A (en) | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
EP3870611A1 (en) | 2018-10-26 | 2021-09-01 | TeneoBio, Inc. | Heavy chain antibodies binding to cd38 |
WO2020169755A2 (en) | 2019-02-20 | 2020-08-27 | Harbour Antibodies Bv | Antibodies |
JOP20210253A1 (ar) | 2019-04-05 | 2023-01-30 | Teneobio Inc | أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma |
MX2021015045A (es) | 2019-06-07 | 2022-03-17 | Amgen Inc | Construcciones de unión biespecíficas. |
KR20220020810A (ko) | 2019-06-14 | 2022-02-21 | 테네오바이오, 인코포레이티드 | Cd22와 cd3에 결합하는 다중특이적 중쇄 항체 |
CN114555809A (zh) * | 2019-08-28 | 2022-05-27 | 森迪生物科学公司 | 组合癌症免疫疗法 |
EP4077391A1 (en) | 2019-12-18 | 2022-10-26 | Teneofour, Inc. | Heavy chain antibodies binding to cd38 |
GB202003632D0 (en) | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
AU2021263926A1 (en) | 2020-04-29 | 2023-01-19 | Teneoone, Inc. | Methods of treating multiple myeloma |
PE20230431A1 (es) | 2020-04-29 | 2023-03-08 | Teneobio Inc | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas |
TW202330622A (zh) | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
CA3184351A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
CR20220656A (es) | 2020-06-30 | 2023-03-01 | Teneobio Inc | Unión de anticuerpos multiespecíficos a bcma |
IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
GB202017555D0 (en) | 2020-11-06 | 2020-12-23 | Harbour Antibodies Bv | Antibody-conjugated nanoparticles |
TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
MX2023006573A (es) | 2020-12-03 | 2023-06-19 | Amgen Inc | Constructos de inmunoglobulina con multiples dominios de union. |
JP2024500251A (ja) | 2020-12-09 | 2024-01-05 | トリアンニ,インコーポレーテッド | 重鎖のみ抗体 |
IL303626A (en) | 2020-12-16 | 2023-08-01 | Regeneron Pharma | Mice expressing human FC alpha receptors |
CA3209052A1 (en) | 2021-02-19 | 2022-08-25 | Rafael Cristian CASELLAS | Single domain antibodies that neutralize sars-cov-2 |
CA3211138A1 (en) | 2021-02-25 | 2022-09-01 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
KR20230150825A (ko) | 2021-02-26 | 2023-10-31 | 테네오바이오, 인코포레이티드 | 항-muc1-c 항체 및 car-t 구조 |
TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
CA3214283A1 (en) | 2021-04-06 | 2022-10-13 | Teneobio, Inc. | Anti-cd19 antibodies and car-t structures |
JP2024513951A (ja) | 2021-04-16 | 2024-03-27 | テネオバイオ, インコーポレイテッド | 抗cd20抗体及びcar-t構造 |
EP4333614A1 (en) * | 2021-05-05 | 2024-03-13 | Leveragen, Inc. | Engineered non-human animals for producing antibodies |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
WO2023036982A1 (en) | 2021-09-10 | 2023-03-16 | Harbour Antibodies Bv | Anti-sars2-s antibodies |
GB202112935D0 (en) | 2021-09-10 | 2021-10-27 | Harbour Antibodies Bv | Sars-cov-2 (sars2, covid-19) heavy chain only antibodies |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0143151A3 (en) | 1980-08-11 | 1985-07-10 | BAUSCH & LOMB INCORPORATED | Apparatus for use in an ophthalmic instrument |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
EP1026240A3 (en) | 1988-09-02 | 2004-04-07 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5843440A (en) | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
WO1992005801A1 (en) | 1990-10-04 | 1992-04-16 | University Of Virginia Alumni Patents Foundation | Primate erythrocyte bound monoclonal antibody heteropolymers |
PT1498427E (pt) * | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
WO1998021355A1 (en) * | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
EP0954978B1 (en) * | 1998-03-12 | 2011-11-30 | VHsquared Limited | New products comprising inactivated yeasts or moulds provided with active antibodies |
US7083950B2 (en) † | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
AU2001284703B2 (en) * | 2000-08-03 | 2007-03-22 | Therapeutic Human Polyclonals Inc. | Production of humanized antibodies in transgenic animals |
EP1305425A2 (en) | 2000-08-04 | 2003-05-02 | Incyte Genomics, Inc. | Drug metabolizing enzymes |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
EP1417232B1 (en) | 2001-06-13 | 2014-12-03 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
JP4303105B2 (ja) * | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
US6880232B2 (en) | 2001-09-26 | 2005-04-19 | Intel Corporation | Method of making an electrical inductor using a sacrificial electrode |
JP2005289809A (ja) * | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
US6755339B2 (en) † | 2002-06-21 | 2004-06-29 | Delphi Technologies, Inc. | Fluxing apparatus for applying powdered flux |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
GB0218030D0 (en) | 2002-08-02 | 2002-09-11 | Minos Biosystems | Multi-submit protein production system |
GB0228210D0 (en) * | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
US7534604B2 (en) * | 2004-01-16 | 2009-05-19 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
KR101457753B1 (ko) * | 2004-07-22 | 2014-11-03 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 결합 분자 |
CA2584814A1 (en) | 2004-10-22 | 2006-05-04 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglobulin expression in non-human transgenic animals |
EP1844073A1 (en) | 2005-01-31 | 2007-10-17 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
CN101213214B (zh) | 2005-05-20 | 2014-06-25 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
BRPI0706750A2 (pt) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
GB0618345D0 (en) | 2006-09-18 | 2006-10-25 | Univ Erasmus | Binding molecules |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US7731969B1 (en) | 2006-12-06 | 2010-06-08 | Neoclone Biotechnology International, Llc | Methods for developing and producing antigen-specific antibody-producing cells |
PT2152880E (pt) | 2007-06-01 | 2011-12-15 | Omt Inc | Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
SG181477A1 (en) | 2009-12-10 | 2012-07-30 | Regeneron Pharma | Mice that make heavy chain antibodies |
PL2738258T5 (pl) | 2011-02-25 | 2023-05-15 | Regeneron Pharmaceuticals, Inc. | Myszy adam6 |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
PT3653049T (pt) | 2012-12-14 | 2023-11-14 | Omniab Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
-
2005
- 2005-07-22 KR KR1020117019563A patent/KR101457753B1/ko active IP Right Review Request
- 2005-07-22 EP EP10179784.3A patent/EP2311874B1/en active Active
- 2005-07-22 AU AU2005263994A patent/AU2005263994B2/en active Active
- 2005-07-22 SI SI200532162T patent/SI2311874T1/sl unknown
- 2005-07-22 CA CA2580336A patent/CA2580336C/en active Active
- 2005-07-22 CN CN201210057684.XA patent/CN102659941B/zh active Active
- 2005-07-22 SG SG2013004643A patent/SG188080A1/en unknown
- 2005-07-22 KR KR1020077004055A patent/KR101422286B1/ko active IP Right Grant
- 2005-07-22 DK DK05766644.8T patent/DK1776383T3/da active
- 2005-07-22 US US11/658,361 patent/US20090285805A1/en not_active Abandoned
- 2005-07-22 EP EP05766644.8A patent/EP1776383B1/en not_active Revoked
- 2005-07-22 EP EP08075481A patent/EP1978032A3/en not_active Withdrawn
- 2005-07-22 DK DK07075586.3T patent/DK1864998T4/da active
- 2005-07-22 EP EP07075586.3A patent/EP1864998B2/en active Active
- 2005-07-22 PL PL05766644T patent/PL1776383T3/pl unknown
- 2005-07-22 EP EP23218163.6A patent/EP4353819A2/en active Pending
- 2005-07-22 ES ES10179784.3T patent/ES2635497T3/es active Active
- 2005-07-22 RU RU2007106728/13A patent/RU2398882C2/ru active
- 2005-07-22 DK DK10179784.3T patent/DK2311874T3/en active
- 2005-07-22 PL PL10179784T patent/PL2311874T3/pl unknown
- 2005-07-22 KR KR1020107026625A patent/KR101151957B1/ko active IP Right Grant
- 2005-07-22 CN CN201210057668.0A patent/CN102659940B/zh active Active
- 2005-07-22 SI SI200531906T patent/SI1776383T1/sl unknown
- 2005-07-22 PT PT57666448T patent/PT1776383E/pt unknown
- 2005-07-22 HU HUE10179784A patent/HUE034335T2/en unknown
- 2005-07-22 KR KR1020127016031A patent/KR101443473B1/ko active IP Right Grant
- 2005-07-22 PT PT101797843T patent/PT2311874T/pt unknown
- 2005-07-22 BR BRPI0513577-0A patent/BRPI0513577A/pt active Search and Examination
- 2005-07-22 EP EP17173113.6A patent/EP3272770B1/en active Active
- 2005-07-22 MX MX2007000921A patent/MX2007000921A/es active IP Right Grant
- 2005-07-22 LT LTEP10179784.3T patent/LT2311874T/lt unknown
- 2005-07-22 ES ES05766644.8T patent/ES2523661T3/es active Active
- 2005-07-22 ES ES07075586T patent/ES2440990T5/es active Active
- 2005-07-22 JP JP2007522034A patent/JP2008512987A/ja active Pending
- 2005-07-22 WO PCT/GB2005/002892 patent/WO2006008548A2/en active Application Filing
-
2007
- 2007-01-22 MX MX2012000436A patent/MX338603B/es unknown
- 2007-02-09 ZA ZA2007/01186A patent/ZA200701186B/en unknown
-
2008
- 2008-02-26 ZA ZA2008/01820A patent/ZA200801820B/en unknown
-
2009
- 2009-12-23 US US12/645,653 patent/US8921522B2/en active Active
- 2009-12-23 US US12/645,684 patent/US8921524B2/en active Active
-
2010
- 2010-08-24 AU AU2010212518A patent/AU2010212518B2/en active Active
-
2011
- 2011-01-25 US US13/013,156 patent/US20110118444A1/en active Pending
- 2011-07-29 JP JP2011166561A patent/JP5855381B2/ja active Active
- 2011-07-29 JP JP2011166562A patent/JP5888893B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-25 ZA ZA2013/01416A patent/ZA201301416B/en unknown
- 2013-03-15 US US13/837,402 patent/US9353179B2/en active Active
- 2013-03-15 US US13/837,520 patent/US9346877B2/en active Active
-
2014
- 2014-11-17 CY CY20141100953T patent/CY1115762T1/el unknown
-
2017
- 2017-08-11 CY CY20171100869T patent/CY1119561T1/el unknown
-
2018
- 2018-04-16 US US15/953,622 patent/US10906970B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201301416B (en) | Binding molecules | |
ZA200810117B (en) | Cripto binding molecules | |
GB0510790D0 (en) | Anti-CD16 binding molecules | |
GB0601513D0 (en) | Binding molecules 3 | |
EP1827245A4 (en) | BINDING COMPONENT | |
EP1907001A4 (en) | ILT3 BONDING MOLECULES AND ITS USES | |
IL182139A0 (en) | MODIFIED Fc MOLECULES | |
GB0521991D0 (en) | Siglec-9 binding agents | |
ZA200901815B (en) | Binding molecules | |
IL182279A0 (en) | Angiopoietin-2-specific binding agents | |
GB0404187D0 (en) | Binding agents | |
EP1710096A4 (en) | BINDING DEVICE | |
EP1966603A4 (en) | FIXING MOLECULES | |
PL1735347T3 (pl) | Specyficznie wiążące cząsteczki przeciwko synaptofizynie | |
GB0601511D0 (en) | Binding Molecules 2 | |
GB0520523D0 (en) | Object binding | |
GB0410983D0 (en) | Molecules | |
GB0410627D0 (en) | Specific binding members | |
EP1590431A4 (en) | ALPHA TUMOR NECROSIS FACTOR MOLECULES | |
GB0406342D0 (en) | Molecules | |
GB0511881D0 (en) | Binding molecules | |
GB0327532D0 (en) | Specific binding molecules | |
PL366676A1 (en) | Binding spacer | |
GB0502913D0 (en) | Binding sites | |
GB0522320D0 (en) | Binding apparatus |